Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 5/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.47 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.47 |
| ▸ | EIF4E | P06730 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.45 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.45 |
| ▸ | KDR | P35968 | 2/20 | 0.45 |
| ▸ | CCNC | P24863 | 1/20 | 0.45 |
| ▸ | CDK8 | P49336 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL2932794 | 0.93 | RIPK1 (0.52) | RIPK1POLBSMN1; SMN2CYP11B2JAK2 | |
| SCHEMBL2931827 | 0.88 | RIPK1 (0.59) | RIPK1POLBMKNK1MKNK2HPGD | |
| SCHEMBL2927882 | 0.87 | RIPK1 (0.55) | RIPK1POLBSMN1; SMN2JAK2MKNK1 | |
| Hydrochloric Acid SCHEMBL2935656 | 0.86 | RIPK1 (0.54) | RIPK1POLBSMN1; SMN2JAK2MKNK1 | |
| Trifluoroacetic Acid SCHEMBL4886432 | 0.82 | RIPK1 (0.52) | RIPK1POLBHPGDKDRCCNC | |
| SCHEMBL14269575 | 0.80 | CASP3 (0.55) | MKNK1MKNK2HPGDCDK5CDK5R1 | |
| SCHEMBL2933095 | 0.79 | CASP3 (0.53) | MKNK1MKNK2HPGDCDK5CDK5R1 | |
| SCHEMBL2932607 | 0.79 | ATR (0.63) | RIPK1HPGD | |
| SCHEMBL2928571 | 0.79 | BTK (0.53) | RIPK1POLBSMN1; SMN2JAK2HPGD | |
| SCHEMBL2933094 | 0.78 | CDK5 (0.52) | POLBMKNK1MKNK2HPGDCDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044051-B1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB PUBL (SE) | 2010-01-27 | — | — | EP | claimed |
| US-20080039450-A1 | Compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-02-14 | — | — | US | claimed |
| EP-2044051-B1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB PUBL (SE) | 2010-01-27 | — | — | EP | disclosed |
| US-20080039450-A1 | Compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-02-14 | — | — | US | disclosed |
| US-20080039450-A1 | Compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-02-14 | — | — | US | disclosed |
| WO-2007147874-A1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB (PUBL) (SE) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039450-A1 | Compounds | NEK2, CSNK2A3, CSNK2A1 | RIPK1 592/4885POLB 1721/4885SMN1; SMN2 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.